Skip to main content

Amyloidogenic Transthyretin Amyloidosis News

Related terms: Transthyretin-Related Amyloidosis, hATTR, Hereditary Transthyretin-Related Amyloidosis

FDA OKs Amvuttra To Treat Heart Conditions

MONDAY, March 24, 2025 – The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of people.  The drug, called Amvuttra (vutrisiran), ...

FDA Approves Wainua (eplontersen) for the Treatment of Adults with Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

U.S. FDA approval based on Phase 3 NEURO-TTRansform results showing Wainua demonstrated consistent and sustained benefit halting neuropathy disease progression and improving neuropathy impairment...

FDA Approves Amvuttra (vutrisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 13, 2022-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the U.S. Food and Drug Administration...

FDA Approves Tegsedi (inotersen) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis

BOSTON and CARLSBAD, Calif., Oct. 05, 2018 (GLOBE NEWSWIRE) – Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS),...

FDA Approves Onpattro (patisiran) Targeted RNA-based Therapy for Polyneuropathy Caused by hATTR

August 10, 2018 – The U.S. Food and Drug Administration today approved Onpattro (patisiran) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary...

Ask a question

To post your own question to our community, sign in or create an account.